Recent News & Research

ResearchTreatments

Highlights in Lung Cancer From ESMO 2021

*September 2021* Dr. Pasi Jänne, MD, PhD, discusses promising studies from the meeting in this video. Transcript: A couple of them include the DESTINY-Lung trial, which was the trial of trastuzumab deruxtecan , a HER2 antibody drug conjugate in patients with HER2 mutant lung cancer. So this is a subset of…
laurabbook@gmail.com
November 10, 2021
ResearchTreatments

Amivantamab with lazertinib for patients with chemotherapy-naïve NSCLC with EGFR mutations who have experienced relapse on or after osimertinib therapy

*August 2021* DR LOVE: So let’s talk about some of the papers presented at ASCO related to targeted therapy, and one you commented on in your talk was the CHRYSALIS study looking at the amivantamab bispecific along with lazertinib, which I guess is a lot like osimertinib. Can you talk a…
laurabbook@gmail.com
November 10, 2021
ResearchTreatments

BLU-945 Clinical Trial Is Open for Triple Mutant EGFR

*September 2021* From Blueprint Medicines:  Currently, there are no approved therapies for patients with osimertinib-resistant EGFRm NSCLC, and there is an urgent need for new therapies to address tumor resistance. BLU-945 was designed to potently inhibit triple-mutant EGFR harboring either the activating L858R or exon 19 deletion mutations combined with…
laurabbook@gmail.com
November 10, 2021
ResearchTreatments

Variant of NSCLC vs EGFR Mutations

*August 2021* A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients. View the entire transcript or watch the video here. Alexander I. Spira, MD, PhD, FACP: I know we talked a little bit about this before,…
laurabbook@gmail.com
November 10, 2021